Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816109 | 0.87 | PARP1 (0.33) | PARP1PNMTTYMS | |
| SCHEMBL6822909 | 0.87 | PARP1 (0.33) | PARP1PNMTTYMS | |
| SCHEMBL29861488 | 0.77 | IDO1 (0.31) | — | |
| SCHEMBL23326396 | 0.77 | IDO1 (0.31) | — | |
| SCHEMBL20562184 | 0.75 | RXFP1 (0.36) | PARP1PRNPMEN1KMT2A | |
| SCHEMBL6820382 | 0.75 | PARP1 (0.35) | PARP1PNMTTYMSPRNPMEN1 | |
| SCHEMBL6816725 | 0.73 | PARP1 (0.35) | PARP1PNMTTYMSPRNPBACE1 | |
| SCHEMBL1770665 | 0.71 | ALDH1A1 (0.33) | AHR | |
| SCHEMBL1248415 | 0.71 | PARP1 (0.50) | PARP1PNMTTYMSPRNPBACE1 | |
| SCHEMBL29375428 | 0.71 | PARP1 (0.54) | PARP1PNMTTYMSPRNPBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995734-B1 | Method for production of halogen-containing aromatic compound | NIPPON CATALYTIC CHEM IND (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6433231-B2 | BROMINATION THE CORRESPONDING NAPHTHALENE HALOGEN COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | NIPPON SHOKUBAI CO., LTD., A JAPAN CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-6288290-B1 | BROMINATION AND PHOTOBROMINATION OF AROMATIC COMPOUNDS | NIPPON SHOKUBAI, CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0995734-A1 | Method for production of halogen-containing aromatic compound | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | CBR1, CBR3, DCXR | PARP1 1040/4885PNMT 3110/4885TYMS 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.